Milestone Pharma falls after TD Cowen downgrades to "hold", removes PT
Shares of drug developer Milestone Pharmaceuticals MIST.O fall 8% to 73 cents, extending decline to third day
Brokerage TD Cowen downgrades MIST to "hold" from "buy", removes PT
Cites etripamil's regulatory and commercial timing uncertainty
"The lack of clarity on regulatory timelines puts additional strain on the company's limited capital," says brokerage
MIST shares fell ~61% on Friday after the U.S. FDA declined to approve its nasal spray, Cardamyst, to treat a type of heart condition
Including session moves, MIST stock down ~69% YTD compared to ~5% decline in the S&P 500 index .SPX
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Intel Q1 Earnings Preview: Triple Test of CPU, 18A Yields and Foundry Orders

Allbirds Ditches Sneakers and Pivots to AI Computing - Is BIRD Stock Still Worth Buying After a 600% Surge?

Bitcoin Breaks $78,000 Amid U.S.-Iran Conflict, Can It Return to $100,000 in 2026?

Asia-Pacific Stocks Rise Across the Board Monday as Easing Middle East Tensions Boost Market Sentiment

Nvidia Launches Ising Model Driving Quantum Sector Surge, QUBT vs IONQ, Which Is More Worth Investing In?

Tradingkey








